Fujifilm Begins BioProcess Innovation Center Expansion Project


Expected to be ready by mid-2024

Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO) for biologics, viral vaccines and viral vectors, held a groundbreaking ceremony for the expansion of its BioProcess Innovation Center in Research Triangle Park in North Carolina.

The BioProcess Innovation Center—which originally opened in May 2016 as a three-story, 62,000 square-foot facility for process invention, process design and development, and product characterization—is expected to be completed and the capacity operational by mid-2024.

According to the company, the expansion will be doubling the site’s current laboratory footprint with an addition of 89,000 square feet that will feature analytical instrumentation, high-throughput bioprocessing equipment, and automation technologies through a collaboration with sister Fujifilm company, Fujifilm Wako Chemicals U.S.A., Corporation. The added labs and technology are expected to enhance the CDMO’s capabilities as a development and analytical service provider by expanding upon its offerings including process characterization, drug substance formulation and quality control testing, and adding new services such as drug product formulation development.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.